+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Radionuclide Drug Conjugate Market - Global Forecast 2025-2030- Product Image
Radionuclide Drug Conjugate Market - Global Forecast 2025-2030- Product Image
Sale

Radionuclide Drug Conjugate Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6127152
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Radionuclide drug conjugates are revolutionizing targeted oncology by merging nuclear medicine with precision therapeutics. Senior leaders seeking a clear view of this evolving market will find new competitive advantages as technological, regulatory, and collaborative trends reshape patient care.

Market Snapshot of the Radionuclide Drug Conjugates Market

The radionuclide drug conjugates market is transitioning from clinical innovation to commercial adoption, propelled by advances in isotope production, chelation chemistry, and digital health. Strategic collaborations among pharmaceutical manufacturers, academic centers, and contract research organizations are catalyzing development, regulatory harmonization, and scalable manufacturing. As pioneering therapies secure expedited approvals, stakeholders including clinicians, investors, and payers are reevaluating in-market strategies and access pathways, reflecting the sector’s dynamic shift. Investment in infrastructure, clinical trials, and data-driven patient management is establishing a solid framework for sustainable growth across major regions and diverse oncology indications.

Scope & Segmentation of the Radionuclide Drug Conjugates Market

  • Distribution Channel: Hospital pharmacies, online pharmacy solutions, and emerging retail pharmacy platforms offer differentiated access, integrated care logistics, and adaptive delivery frameworks.
  • Emission Type: Alpha emitters deliver targeted, high-energy cytotoxicity for precise applications; beta emitters provide broader tissue penetration for select tumor environments.
  • End User: Academic hospitals, community hospitals, research institutes, and specialty clinics form the healthcare infrastructure for deployment and trial initiation.
  • Targeting Molecule: Monoclonal antibodies, peptides, and small molecules broaden specificity, off-target minimization, and address challenging indications such as blood-brain barrier penetration.
  • Indication: Key focus on neuroendocrine tumors and prostate cancer highlights leading clinical applications.
  • Region: Americas, Europe, Middle East & Africa, and Asia-Pacific demonstrate variable market adoption, growth potential, and regulatory complexity. Regional trends are shaped by infrastructure investment, public and private partnerships, and workforce expertise.
  • Key Innovators: Industry leaders including Novartis AG, Lantheus Holdings, Curium Pharma S.A., Bayer AG, and emerging firms such as Point Biopharma Solutions and Telix Pharmaceuticals are advancing commercialization and partnership models.

Key Takeaways for Senior Decision-Makers

  • Radionuclide drug conjugates enable next-generation precision oncology, leveraging disease-specific vectors that minimize toxicity and enhance therapeutic outcomes across resistant cancer types.
  • Technological synergies—including AI in patient stratification and dosimetry—are optimizing treatment efficacy, paving the way for more personalized, outcome-driven protocols.
  • Streamlined regulatory pathways and harmonized guidelines are shortening timelines from research to clinical deployment, increasing market responsiveness and competitive differentiation.
  • Industry alliances foster risk-sharing and vertical integration, empowering market participants to jointly navigate complex supply chains while accelerating innovation cycles.
  • Healthcare systems globally are actively evaluating access and reimbursement frameworks, in response to evolving clinical evidence and shifting economic incentives.

Tariff Impact on Domestic Radiopharmaceutical Supply Chains

Recently enacted trade measures have increased procurement complexity and production costs for radionuclide inputs in the United States. Tariffs affecting imported isotopes, precursor chemicals, and specialized equipment disrupt time-sensitive manufacturing, driving a sector-wide pivot toward regional supply chain resilience. Stakeholders are responding with diversified sourcing, local partnerships, and investments in multipurpose domestic infrastructure. Policy advocacy and engagement with federal agencies are strengthening clinical continuity and inventory management in this evolving regulatory environment.

Methodology & Data Sources

This report is grounded in primary research, including in-depth interviews with leaders across clinical oncology, radiopharmacy, and regulatory affairs. Insights are validated by technical workshops with isotope chemists and supply chain specialists. Additional data is sourced from peer-reviewed literature, regulatory guidelines, industry conferences, and company disclosures, analyzed using data triangulation and independent expert review to ensure accuracy.

Why This Report Matters

  • Delivers a strategic view of segment trends, technology applications, and competitive positioning.
  • Empowers decision-makers to proactively address regulatory, supply chain, and partnership challenges to maintain market leadership.
  • Supports informed planning for investment, market entry, and healthcare delivery innovation in a complex global landscape.

Conclusion

The radionuclide drug conjugates market is defined by innovation, regulatory adaptation, and strategic collaboration. Forward-looking organizations can leverage these insights to confidently navigate the complexities and accelerate leadership in precision oncology therapeutics.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of alpha-emitter targeted RDCs for improved therapeutic index in metastatic cancers
5.2. Expansion of kit-based radioisotope conjugate manufacturing to accelerate decentralized hospital preparation
5.3. Advancements in bifunctional chelator technology for enhanced in vivo stability of radionuclide drug conjugates
5.4. Integration of theranostic imaging and therapy using dual-labeled radionuclide conjugates for personalized treatment
5.5. Strategic partnerships between biotech firms and isotope suppliers to secure supply chain resilience for therapeutic radionuclides
5.6. Regulatory framework evolution supporting expedited approval pathways for radionuclide drug conjugates in oncology
5.7. Development of lutetium-177 and actinium-225 conjugates targeting novel tumor-associated antigens for refractory cancers
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Radionuclide Drug Conjugate Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Radionuclide Drug Conjugate Market, by Emission Type
9.1. Introduction
9.2. Alpha Emitter
9.3. Beta Emitter
10. Radionuclide Drug Conjugate Market, by End User
10.1. Introduction
10.2. Hospital
10.2.1. Academic Hospital
10.2.2. Community Hospital
10.3. Research Institute
10.4. Specialty Clinic
11. Radionuclide Drug Conjugate Market, by Targeting Molecule
11.1. Introduction
11.2. Monoclonal Antibody
11.3. Peptide
11.4. Small Molecule
12. Radionuclide Drug Conjugate Market, by Indication
12.1. Introduction
12.2. Neuroendocrine Tumor
12.3. Prostate Cancer
13. Americas Radionuclide Drug Conjugate Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Radionuclide Drug Conjugate Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Radionuclide Drug Conjugate Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Novartis AG
16.3.2. Lantheus Holdings, Inc.
16.3.3. Curium Pharma S.A.
16.3.4. Bayer AG
16.3.5. Ion Beam Applications S.A.
16.3.6. Jubilant Pharmova Limited
16.3.7. Eckert & Ziegler Strahlen- und Medizintechnik AG
16.3.8. Telix Pharmaceuticals Limited
16.3.9. Nordion Inc.
16.3.10. Point Biopharma Solutions, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. RADIONUCLIDE DRUG CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. RADIONUCLIDE DRUG CONJUGATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. RADIONUCLIDE DRUG CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. RADIONUCLIDE DRUG CONJUGATE MARKET: RESEARCHAI
FIGURE 26. RADIONUCLIDE DRUG CONJUGATE MARKET: RESEARCHSTATISTICS
FIGURE 27. RADIONUCLIDE DRUG CONJUGATE MARKET: RESEARCHCONTACTS
FIGURE 28. RADIONUCLIDE DRUG CONJUGATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. RADIONUCLIDE DRUG CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ALPHA EMITTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY BETA EMITTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY NEUROENDOCRINE TUMOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 79. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 82. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 83. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 86. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 87. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 88. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 89. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 90. CANADA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 91. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 94. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 95. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 98. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 99. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 100. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 101. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 102. MEXICO RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 156. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 157. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 160. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 161. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 162. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 163. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. GERMANY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 168. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 169. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 172. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 173. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 174. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 175. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 176. FRANCE RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 192. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 193. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 196. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 197. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 198. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 199. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. ITALY RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 204. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 205. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 208. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 209. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 210. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 211. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. SPAIN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 252. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 253. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 256. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 257. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 258. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 259. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 260. DENMARK RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 273. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 274. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 275. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 276. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 277. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 280. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 281. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 282. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 283. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 284. QATAR RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 285. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 288. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 289. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 292. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 293. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 294. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 295. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 296. FINLAND RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 297. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 300. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY HOSPITAL, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY TARGETING MOLECULE, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2018-2024 (USD MILLION)
TABLE 312. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY EMISSION TYPE, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA RADIONUCLIDE DRUG CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA RADIONUCLIDE DRUG CONJUGA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Radionuclide Drug Conjugate market report include:
  • Novartis AG
  • Lantheus Holdings, Inc.
  • Curium Pharma S.A.
  • Bayer AG
  • Ion Beam Applications S.A.
  • Jubilant Pharmova Limited
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • Telix Pharmaceuticals Limited
  • Nordion Inc.
  • Point Biopharma Solutions, Inc.

Related Reports

Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2025-2030 - Product Image

Targeted PSMA Radionuclide Drug Conjugates Market - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2025-2030 - Product Image

Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Next Generation Drug Conjugates Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Next Generation Drug Conjugates Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, Type of Payload, Type of Therapy, Route of Administration, Key Target Indications and Key Geographical Regions - Product Image

Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, Type of Payload, Type of Therapy, Route of Administration, Key Target Indications and Key Geographical Regions

  • Report
  • 120 Pages
  • Global
From
Next Generation Drug Conjugates Market Report 2025 - Product Image

Next Generation Drug Conjugates Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.